துணிகர மூலதனம் வ்ஸீ News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from துணிகர மூலதனம் வ்ஸீ. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In துணிகர மூலதனம் வ்ஸீ Today - Breaking & Trending Today

Flagship's Repertoire bags $189M to go after immune targets


John Cox, Repertoire s CEO (left) and Douglas Cole, M.D., Repertoire s chairman (Repertoire)
Repertoire Immune Medicines has raised $189 million to advance anti-cancer T-cell therapies through the clinic while expanding its immune response drug discovery platform.
Flagship Pioneering created Repertoire by combining two of its portfolio companies, Cogen Immune Medicines and Torque Therapeutics. The VC shop oversaw the merger to bring together the immune decoding and immuno-oncology platforms that underpinned Cogen and Torque, respectively, and put former Bioverativ CEO John Cox in charge of the combined company.
Now, Repertoire has raised a series B round to support the next stage of its development. Repertoire framed the financing primarily in the context of what it will mean for the DECODE technologies it has developed to characterize the immune synapse.   ....

United States , John Cox , Softbank Vision Fund , Alaska Permanent Fund , Repertoire Immune Medicines , Cogen Immune Medicines , Public Sector Pension Investment Board , Flagship Pioneering , Venture Capital Vc , Cell Therapy , Cell Amp Gene Therapy , Immuno Oncology , ஒன்றுபட்டது மாநிலங்களில் , ஜான் காக்ஸ் , சாப்ட் பேங்க் பார்வை நிதி , அலாஸ்கா நிரந்தர நிதி , கோஜன் நோய் எதிர்ப்பு சக்தி மருந்துகள் , பொது துறை ஓய்வூதியம் முதலீடு பலகை , துணிகர மூலதனம் வ்ஸீ , செல் சிகிச்சை , செல் ஆம்ப் கீந் சிகிச்சை , இம்யூனோ புற்றுநோயியல் ,

Bionaut Labs launches with plans to attack brain tumors with tiny, guided robots


Mar 3, 2021 3:05am
Bionaut Labs small, remote-controlled devices can overcome the obvious constraint that holds back surgical drills, probes and needles: once they’re in the body, they can’t turn. (Getty Images)
The robots are coming: After working under the radar for four years, Bionaut Labs is raising the curtain on its tiny, remote-controlled devices, built to travel through the human body and deliver a dose of medicine where it’s needed the most.
Smaller than a millimeter and with a few moving parts, the tiny voyagers are designed to navigate through tissues and go where today’s surgeons cannot, such as when dealing with hard-to-reach cancers. ....

Neurocrine Biosciences , Errol Desouza , Vinod Khosla , Michael Shpigelmacher , Insights For The Life Sciences Industry , Bionaut Labs , Making Insights , Life Sciences , Jon Mckee Photography , Los Angeles Based , Khosla Ventures , Upfront Ventures , Venture Capital Vc , Medical Device , Glioblastoma Multiforme Gbm , Robotic Surgery , எரொல் டெசௌசா , வினோத் கோசில , நுண்ணறிவு க்கு தி வாழ்க்கை அறிவியல் தொழில் , தயாரித்தல் நுண்ணறிவு , வாழ்க்கை அறிவியல் , ஜான் மகீ புகைப்படம் எடுத்தல் , லாஸ் ஏஞ்சல்ஸ் அடிப்படையிலானது , கோசில முயற்சிகள் , வெளிப்படையான முயற்சிகள் , துணிகர மூலதனம் வ்ஸீ ,

European VC Sofinnova Partners raises $540M late-stage crossover healthcare fund


(Pixabay)
Sofinnova Partners has pulled in a healthy €445 million ($540 million) in its latest capital raise as the European venture capital firm seeks out late-stage plays in biotech and medtech.
The fund was “oversubscribed and significantly exceeded its target,” the Paris-based firm said, and with this latest cash boost it s set to continue its focus on European clinical-stage companies “needing scale-up capital” while also supporting “best-in-class companies” in the U.S. and elsewhere.
It did, not however, detail any particular targets it was going after. Other VC firms have said in a COVID-19 world they would focus more on conditions such as infectious diseases and other neglected R&D areas. ....

France General , Antoine Papiernik , Insights For The Life Sciences Industry , Sofinnova Partners , Making Insights , Life Sciences , Venture Capital Vc , பிரான்ஸ் ஜநரல் , அன்டோயின் பப்பிேர்னிக் , நுண்ணறிவு க்கு தி வாழ்க்கை அறிவியல் தொழில் , தயாரித்தல் நுண்ணறிவு , வாழ்க்கை அறிவியல் , நிதி திரட்டல் , துணிகர மூலதனம் வ்ஸீ ,

FogPharma comes through the clearing with a meaty $107M raise for 'undruggable' targets


(Getty Images)
It’s been a relatively quiet few years for FogPharma, at least publicly, but now the Cambridge, Massachusetts-based biotech is revealing a major funding round.
The series C has been pumped up to $107 million from a who’s who of venture capitalists. The round was led by venBio Partners with help from new investors Cormorant Asset Management, Farallon Capital Management, Invus, funds and accounts advised by T. Rowe Price Associates Inc., HBM Healthcare Investments, Casdin Capital and PagsGroup.
Existing investors also chipped in, including Google’s GV, 6 Dimensions Capital, Deerfield Management and Blue Pool Capital.
What has them opening their checkbooks? FogPharma’s platform direct beta-catenin antagonist and universal druggability platform. Out of this has come its lead program, a beta-catenin antagonist designed to treat previously undruggable cancers. ....

United Kingdom , United States , Gregory Verdine , Insights For The Life Sciences Industry , T Rowe Price Associates Inc , Bio Partners , Cormorant Asset Management , Farallon Capital Management , Price Associates Inc , Casdin Capital , Deerfield Management , Blue Pool , Making Insights , Life Sciences , Venture Capital Vc , Cancer Drugs , ஒன்றுபட்டது கிஂக்டம் , ஒன்றுபட்டது மாநிலங்களில் , நுண்ணறிவு க்கு தி வாழ்க்கை அறிவியல் தொழில் , டி ரோ ப்ரைஸ் கூட்டாளிகள் இன்க் , உயிர் கூட்டாளர்கள் , கர்மரண்ட் சொத்து மேலாண்மை , ஃபாரல்லன் மூலதனம் மேலாண்மை , ப்ரைஸ் கூட்டாளிகள் இன்க் , தீர்ப்பியல்ட் மேலாண்மை , நீலம் பூல் ,